Tag: medicine

WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis’ common stock to nine newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

SPRINGFIELD, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- The Dr. Louis Krenn Medical Scholarship announces a new opportunity for undergraduate and medical students across the United States to advance their journey toward a career in medicine. This prestigious one-time award, established by Dr. Louis Krenn, a distinguished Family Medicine physician, aims to support the next generation of healthcare professionals who demonstrate a commitment to service, innovation, and compassion. The scholarship, open to students nationwide, invites applicants to share their vision for the future of medicine through a thought-provoking essay.

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. –

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi^® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI^® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –

I risultati dello studio di Fase 3 AMPLITUDE mettono in luce il potenziale di niraparib e abiraterone acetato nel ritardare la progressione del cancro e il peggioramento dei sintomi¹